...
首页> 外文期刊>Science Advances >Targeting dePARylation selectively suppresses DNA repair–defective and PARP inhibitor–resistant malignancies
【24h】

Targeting dePARylation selectively suppresses DNA repair–defective and PARP inhibitor–resistant malignancies

机译:靶向dePARylation选择性抑制DNA修复缺陷和PARP抑制剂耐药的恶性肿瘤

获取原文
           

摘要

While poly(ADP-ribosyl)ation (PARylation) plays an important role in DNA repair, the role of dePARylation in DNA repair remains elusive. Here, we report that a novel small molecule identified from the NCI database, COH34, specifically inhibits poly(ADP-ribose) glycohydrolase (PARG), the major dePARylation enzyme, with nanomolar potency in vitro and in vivo. COH34 binds to the catalytic domain of PARG, thereby prolonging PARylation at DNA lesions and trapping DNA repair factors. This compound induces lethality in cancer cells with DNA repair defects and exhibits antitumor activity in xenograft mouse cancer models. Moreover, COH34 can sensitize tumor cells with DNA repair defects to other DNA-damaging agents, such as topoisomerase I inhibitors and DNA-alkylating agents, which are widely used in cancer chemotherapy. Notably, COH34 also efficiently kills PARP inhibitor–resistant cancer cells. Together, our study reveals the molecular mechanism of PARG in DNA repair and provides an effective strategy for future cancer therapies.
机译:尽管聚(ADP-核糖基)化(PARylation)在DNA修复中起着重要作用,但是dePARylation在DNA修复中的作用仍然难以捉摸。在这里,我们报道从NCI数据库COH34中鉴定出的一种新型小分子,在体外和体内均具有纳摩尔效价,可特异性抑制聚(ADP-核糖)糖水解酶(PARG)(主要的dePARylation酶)。 COH34与PARG的催化域结合,从而延长DNA损伤处的PARylation并捕获DNA修复因子。该化合物在具有DNA修复缺陷的癌细胞中诱导致死性,并在异种移植小鼠癌症模型中表现出抗肿瘤活性。而且,COH34可以使具有DNA修复缺陷的肿瘤细胞对其他DNA破坏剂(例如拓扑异构酶I抑制剂和DNA烷基化剂)敏感,它们广泛用于癌症化学疗法。值得注意的是,COH34还可以有效杀死耐PARP抑制剂的癌细胞。总之,我们的研究揭示了PARG在DNA修复中的分子机制,并为未来的癌症治疗提供了有效的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号